

A clinical trial to test whether treating patients with liver cirrhosis with capsules containing healthy stool bacteria or a dummy capsule (placebo) will reduce the time it takes to develop an infection resulting in hospital admission

Submission date 14/03/2022	Recruitment status Recruiting	☒ Prospectively registered ☐ Protocol
Registration date 25/03/2022	Overall study status Ongoing	☐ Statistical analysis plan ☐ Results
Last Edited 13/02/2026	Condition category Infections and Infestations	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

Background and study aims

Our body contains trillions of bacteria. Many of these live in our bowels which keeps us healthy and helps our immune system to fight against infections. However, an increased number of 'unfriendly' bacteria are found in the bowel of patients with liver cirrhosis (permanent liver damage), which makes them highly susceptible to infections. Antibiotics are becoming less effective as they are used so frequently, and the bowel can become infected with 'super-bugs'.

Replacing the unfriendly bowel bacteria in patients with cirrhosis with healthy bacteria donated from healthy volunteers (faecal microbiota transplantation) could be highly beneficial and reduce antibiotic usage. Findings from the initial FMT trial (the PROFIT trial) showed that FMT administered during endoscopy was safe with no serious side effects. However, patients said that they would prefer to take tablets rather than have an endoscopy.

The researchers have therefore made an FMT capsule from freeze-dried stool and this study will test whether treating patients with these FMT capsules reduces their likelihood of getting an infection.

Who can participate?

Patients aged 18 years and above who have been diagnosed with alcohol-related cirrhosis (ALD) or metabolic dysfunction-associated steatotic liver disease (MASLD) (previously referred to as non-fatty alcoholic fatty liver disease) or MetALD cirrhosis (a combination of the two types of liver disease) at any time point.

What does the study involve?

Participants will be selected at random to take FMT capsules or 'dummy' capsules that contain no FMT (placebo) and both the study team and the participants will not know which treatment

they are taking. The participants will need to take five capsules every 3 months for a total of 21 months or until they develop their first infection leading to hospital admission and will be followed up for a maximum of 2 years. This study will also examine whether FMT reduces the side effects of cirrhosis and has beneficial effects on the liver and immune system. The researchers will look at whether FMT reduces hospital admissions, the incidence of 'super-bug' infections and death. Laboratory studies will look at whether FMT treatment will help the immune system fight infection.

What are the possible benefits and risks of participating?

Patients will be taking part in a new and innovative trial to assess the beneficial effects of FMT capsules in patients with cirrhosis. There are no curative treatments available to patients with cirrhosis, aside from liver transplantation. Unfortunately, due to the scarcity of donor organs, even those listed for transplant can wait months or even years for a new liver. Others are too unwell or frail or deemed ineligible to be listed for a liver transplant.

The researchers will also gather information during the trial on how the FMT works in patients with cirrhosis including the impact on the make-up and function of the gut microbiome. They will examine whether FMT can reduce the likelihood of developing an infection and being admitted to the hospital.

There are no risks involved in taking part with regard to the samples being obtained, and the amount of blood taken will not be harmful to the patient. The placebo treatment is not harmful but is not expected to have any benefit as it contains no active drug or treatment. All patients, regardless of whether they receive placebo or FMT have the same rigorous follow-up and support from the trials team. They will be closely monitored after the treatment is given and will be seen at regular intervals afterwards to see if they have experienced any side effects. The researchers do not anticipate any serious problems to occur after the FMT or placebo treatment, but the participants will be given contact numbers should they run into any problems outside of the trial visits.

Where is the study run from?

King's College London and King's College Hospital NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

November 2021 to June 2028

Who is funding the study?

National Institute for Health Research Efficacy and Mechanism Evaluation (NIHR) (UK)

Who is the main contact?

1. Prof. Debbie Shawcross (Chief Investigator), debbie.shawcross@kcl.ac.uk

2. Ms Sue Cheung, promise@kcl.ac.uk

Contact information

Type(s)

Principal investigator

Contact name

Prof Debbie Shawcross

Contact details

Institute of Liver Studies

King's College Hospital and King's College London

Denmark Hill
London
United Kingdom
SE5 9RS
+44 (0)203 299 3713
debbie.shawcross@kcl.ac.uk

Type(s)

Public

Contact name

Ms Sue Cheung

Contact details

Research Management and Innovation Directorate
Institute of Psychiatry
16 De Crespigny Park
Denmark Hill
King's College London
London
United Kingdom
SE5 8AF
+44 (0)20 7848 0532
promise@kcl.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT06461208

Clinical Trials Information System (CTIS)

2022-000300-35

Integrated Research Application System (IRAS)

1004822

Study information

Scientific Title

A PROspective randomised double-blind parallel-group placebo-controlled multicentre trial of faecal MIcrobiota tranSplantation to improve the primary outcomE (first hospitalisation due to infection) in patients with cirrhosis over 24 months (PROMISE)

Acronym

PROMISE

Study objectives

Current study objectives as of 13/02/2026:

The researchers will perform a clinical trial to test whether treating patients with alcohol-related (ALD), metabolic dysfunction-associated Steatotic liver disease (MASLD) and MetALD cirrhosis with faecal microbiota transplantation (FMT) capsules vs placebo capsules will reduce the likelihood of them getting an infection or decompensating episode by measuring the time it takes to develop an infection or decompensating episode resulting in hospital admission or presentation to the emergency department.

Previous Study objectives:

The researchers will perform a clinical trial to test whether treating patients with alcohol-related and metabolic-associated fatty liver cirrhosis with faecal microbiota transplantation (FMT) capsules vs placebo capsules will reduce the likelihood of them getting an infection by measuring the time it takes to develop an infection resulting in hospital admission.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 16/03/2023, East of England – Cambridge South Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, United Kingdom; +44 (0)207 104 8084; cambridgesouth.rec@hra.nhs.uk), ref: 22/EE/0247

Primary study design

Interventional

Study design

Multicentre randomized double-blind parallel-group placebo-controlled multi-centre trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Infection and decompensation in patients with cirrhosis

Interventions

Randomisation:

Patients will be randomised on a 1:1 basis to either FMT or placebo using the King's Clinical Trial Unit (KCTU) web-based randomisation system. Randomisation will be at the level of the individual using the method of block randomisation with varying block sizes, stratified by site.

Intervention:

Patients will be randomly allocated to two treatment arms:

1. Active treatment - patients assigned to this group will receive the active drug (FMT capsules)
2. The comparison or 'control group': Participants in this group will receive a 'placebo' treatment. The placebo will be a dummy capsule and will NOT contain any stool

The FMT product contains 0.9% sodium chloride and 5% trehalose (cryoprotectant) as excipients. A minimum of 80 g of faeces from a single donor will be used to manufacture one batch of five capsules. Following lyophilisation, the material will be encapsulated in five size 0

delayed-release methylcellulose capsules (DRcaps™, Capsugel®, Livingston, UK). Placebo capsules will contain microcrystalline cellulose. The capsules for the FMT and placebo will be identical in appearance. The capsules are coloured Swedish orange, resulting in an opaque appearance through which the contents cannot be seen. FMT material will be fully traceable from donor to recipient. Aliquots of donor stool will be kept for 30 years to allow for future testing if required.

The patients will need to take five capsules every 3 months. Patients will continue treatment for a total of 21 months or until they develop their first infection leading to hospital admission and will be followed up for a maximum of 2 years at different timepoints - baseline, 30 days (telephone call), 3, 6, 9, 12, 15, 18, 21 and 24 months. At each clinic visit, patients will receive five capsules of the medicine (either the FMT or the placebo) to be taken by mouth and swallowed with water or cordial.

Intervention Type

Biological/Vaccine

Phase

Phase III

Drug/device/biological/vaccine name(s)

Faecal microbiota transplantation (FMT)

Primary outcome(s)

Current primary outcome(s) as of 13/02/2026:

1. Time to first infection resulting in presentation to the Emergency Department (ED) or admission into hospital with a confirmed infection
2. Decompensating episodes as defined in the criteria below:
 - a. Resulting in presentation to the Emergency Department
 - b. Resulting in hospital admission

When the patients meet the primary endpoint, they do not receive further IMP or attend trial visits, but they will continue to be enrolled in the trial for the purposes of monitoring of other clinical endpoints, e.g. all-cause mortality and liver-related mortality.

Previous primary outcome(s):

Time to the first infection resulting in hospital admission i.e., the date the patient is admitted to the hospital due to infection, collected using the King's Clinical Trials Unit Index Hospitalisation (Primary Endpoint) form administered by the research nurse at each clinic visit i.e, 3, 6, 9, 12, 15, 18, 21 and 24 months. When the patients meet the primary endpoint, they do not receive further IMP or attend trial visits, but they will continue to be enrolled in the trial for the purposes of monitoring of other clinical endpoints, e.g. all-cause mortality and liver-related mortality.

Key secondary outcome(s)

Current key secondary outcome(s) as of 13/02/2026:

1. Time to first infection resulting in hospitalisation over 24 month follow up period (former primary endpoint).
2. Incidence of decompensating events including hepatic encephalopathy, new-onset or worsening ascites or variceal bleeding over 24 month follow up period.
3. Incidence of all-cause infection over 24 month follow up period, including infections not resulting in hospitalisation.
4. Progression to ACLF (the development of one or more extrahepatic organ failures)
5. Infection rates and antibiotic usage following randomisation over 24 month follow up period.
6. Incidence of antimicrobial resistance (AMR) including skin and nose colonisation with methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococci* (VRE), extended-spectrum beta-lactamase-producing bacteria (ESBL), fluoroquinolone-resistant Gram-negative and carbapenem-resistant *Enterobacteriales* (over 24 month follow up period).
7. Hospitalisation rates (liver-related and all-cause), including the length of stay and admission to high dependency/intensive care (over 24 month follow up period).
8. Change in liver disease severity scores at 3-, 6-, 12- and 24-months post randomisation.
9. Change in quality of life (EQ-5D-5L score) at 3, 6, 12 and 24 months post-randomisation
10. All-cause mortality and liver-related mortality
11. Change in depression and anxiety scores using HADS at 3, 6, 12 and 24-months post-randomisation
12. Change in alcohol use disorder-related events in patients enrolled with alcohol-related cirrhosis as assessed by the alcohol-use disorders identification test (AUDIT score) at 3, 6, 12 and 24 months post randomisation, and urinary ethyl glucuronide/ethyl sulphate levels if tested as part of the standard of care.
13. Safety of FMT based on safety assessments including physical examination, clinical laboratory evaluation, vital signs and reported as adverse events (AEs) or serious adverse events (SAEs) over 24-month follow-up period.

Previous key secondary outcome(s):

1. Incidence of decompensating events including hepatic encephalopathy, new-onset ascites, variceal bleeding and spontaneous bacterial peritonitis, measured using study-specific laboratory analyses on blood, stool and urine samples at baseline, 3, 6 and 12 months
2. Progression to acute-on-chronic liver failure (ACLF) (the development of one or more organ failures) measured using study-specific laboratory analyses on blood, stool and urine samples at baseline, 3, 6 and 12 months
3. Infection rates and antibiotic usage collected using the concomitant medications log following randomisation
4. Incidence of AMR including skin and nose colonisation with methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococci* (VRE), extended-spectrum beta-lactamase-producing bacteria (ESBL), fluoroquinolone-resistant Gram-negative and carbapenem-resistant *Enterobacteriales*, measured using study-specific laboratory analyses on blood, stool and urine samples at baseline, 3, 6 and 12 months
5. Hospitalisation rates (liver-related and all-cause), including the length of stay and admission to high dependency/intensive care, collected using the King's Clinical Trials Unit Hospitalisation Log and patient medical notes at 3, 6, 9, 12, 15, 18, 21 and 24 months
6. Liver disease severity measured using the Child-Pugh, Model For End-Stage Liver Disease (MELD) and United Kingdom Model for End-Stage Liver Disease (UKELD) scores at baseline, 3, 6, 9, 12, 15, 18, 21 and 24 months
7. Quality of life measured using the EQ-5D-5L questionnaire at baseline, 3, 6, 12 and 24 months
8. All-cause mortality and liver-related mortality collected from patient medical notes and

adverse events log at day 30 over the telephone and thereafter at each clinic visit i.e., 3, 6, 9, 12, 15, 18, 21 and 24 months

9. Depression and anxiety measured using the Hospital Anxiety and Depression Scale (HADS) at baseline, 3, 6, 12 and 24 months

10. Alcohol use disorder-related events in patients enrolled with alcohol-related cirrhosis, measured using the alcohol-use disorders identification test (AUDIT questionnaire) at baseline, 3, 6, 12 and 24 months and urinary ethyl glucuronide/ethyl sulphate levels if tested as part of the standard of care

11. Faecal microbiome composition analysed by sequencing and metabolome analysis at baseline, 3, 6 and 12 months

12. Dietary habits measured using a study-specific dietary questionnaire developed by the team at baseline

Completion date

30/06/2028

Eligibility

Key inclusion criteria

Current key inclusion criteria as of 13/02/2026:

1. Age 18 years or over
2. Confirmed alcohol-related cirrhosis (ALD) or Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) or MetALD cirrhosis based on clinical, radiological and/or histological criteria
3. Model For End-Stage Liver Disease (MELD) score 8-16
4. Patients with alcohol-related cirrhosis who must have an active alcohol consumption on average ≤ 20 grams/day.
5. Patients must be deemed to have the capacity to consent

Previous key inclusion criteria:

1. Age 18 years or over
2. Confirmed alcohol-related cirrhosis or metabolic-associated fatty liver (MAFLD) cirrhosis based on clinical, radiological and/or histological criteria
3. Model For End-Stage Liver Disease (MELD) score 8-16
4. Patients with alcohol-related cirrhosis must have been abstinent for a minimum of 4 weeks prior to randomisation
5. Patients must be deemed to have the capacity to consent (if patients lose capacity during the trial a legal representative will be appointed on their behalf)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 Years

Upper age limit

120 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

Current key exclusion criteria as of 13/02/2026:

1. Moderate, severe or life-threatening food allergy (e.g., peanut allergy)
2. Pregnancy or planned pregnancy. Urine testing will be performed at randomisation to rule out pregnancy in females
3. Breastfeeding
4. Patients treated for acute variceal bleeding, infection, overt hepatic encephalopathy, bacterial peritonitis or ACLF within 14 days prior to randomisation
5. Active alcohol consumption of >20 g/day (1 unit of alcohol contains 10 ml or 8 g of alcohol)
6. Had a previous liver transplant
7. Patients with inflammatory bowel disease
8. Patients with coeliac disease.
9. Patients with a history of prior gastrointestinal resection or surgery that could change the gut microbiome or result in bacterial overgrowth e.g. gastric bypass
10. Active malignancy including hepatocellular carcinoma
11. Patients with an expected life expectancy <6 months or listed for liver transplantation
12. Infected with HIV, hepatitis B or C (patients who have undetectable hepatitis B or C DNA /RNA can be recruited)
13. Patients who have received antibiotics or probiotics (excluding foodstuffs containing 'live bacteria' such as live yoghurts, kefir, fermented vegetables such as sauerkraut/kombucha or cheese) within 7 days prior to randomisation
14. Swallowing disorder, oral-motor dyscoordination or likely inability/unwillingness to ingest study medication
15. Patients who have received another investigational drug or device within 4 months prior to randomisation
16. Patients, who in the opinion of the PI, have a medical condition, or other relevant psychological, familial, or social factor that may jeopardise their health, compliance, or influence the trial integrity in any way.

Previous key exclusion criteria:

1. Severe or life-threatening food allergy (e.g., peanut allergy)
2. Pregnancy or planned pregnancy. Urine testing will be performed at randomisation to rule out pregnancy in females
3. Breastfeeding
4. Patients treated for acute variceal bleeding, infection, overt hepatic encephalopathy, bacterial

peritonitis or ACLF within 14 days prior to randomisation

5. Active alcohol consumption of >20 g/day (1 unit of alcohol contains 10 ml or 8 g of alcohol)

6. Had a previous liver transplant

7. Patients with inflammatory bowel disease

8. Patients with coeliac disease.

9. Patients with a history of prior gastrointestinal resection such as gastric bypass

10. Active malignancy including hepatocellular carcinoma

11. Patients with an expected life expectancy <6 months or listed for liver transplantation

12. Infected with HIV, hepatitis B or C (patients who have undetectable hepatitis B or C DNA /RNA can be recruited)

13. Patients who have received antibiotics or probiotics (excluding foodstuffs containing 'live bacteria' such as live yoghurts, kefir, fermented vegetables such as sauerkraut/kombucha or cheese) within 7 days prior to randomisation

14. Swallowing disorder, oral-motor dyscoordination or likely inability/unwillingness to ingest study medication

15. Patients who have received another investigational drug or device within 4 months prior to randomisation

Date of first enrolment

21/06/2023

Date of final enrolment

31/12/2026

Locations

Countries of recruitment

United Kingdom

England

Scotland

Study participating centre

King's College Hospital

Institute of Liver Studies

Denmark Hill

London

England

SE5 9RS

Study participating centre

St Georges Hospital

Blackshaw Road

London

England

SW17 0QT

Study participating centre

St Mary's Hospital

Praed St
London
England
W2 1NY

Study participating centre

St James University Hospital

Leeds Institute for Data Analytics
Room 6.1, Level 6 Clinical Sciences Building
University of Leeds
Beckett Street
Leeds
England
LS9 7TF

Study participating centre

Freeman Road Hospital

Freeman Road
High Heaton
Newcastle upon Tyne
England
NE7 7DN

Study participating centre

Queens Medical Centre

Nottingham University Hospital
Derby Road
Nottingham
England
NG7 2UH

Study participating centre

Glasgow Royal Infirmary

84 Castle Street
Glasgow
Scotland
G4 0SF

Study participating centre
Ninewells Hospital
Ninewells Avenue
Dundee
Scotland
DD1 9SY

Study participating centre
Queen Elizabeth Hospital
Sherriff Hill
Gateshead
England
NE9 6SX

Study participating centre
Royal Derby Hospital
Uttoxeter Road
Derby
England
DE22 3NE

Study participating centre
Royal Bournemouth Hospital
Castle Lane East
Bournemouth
England
BH7 7DW

Study participating centre
Queen Elizabeth University Hospital
1345 Govan Road
Glasgow
Scotland
G51 4TF

Study participating centre
Hull Royal Infirmary
Anlaby Road

Hull
England
HU3 2JZ

Study participating centre
Derriford Hospital
Derriford Road
Plymouth
England
PL6 8DH

Study participating centre
Bristol Royal Infirmary
Upper Maudlin Street
Bristol
England
BS2 8BJ

Study participating centre
Southmead Hospital
Southmead Road
Westbury-on-trym
Bristol
England
BS10 5NB

Study participating centre
University Hospital Hairmyres
Eaglesham Road
East Kilbride
Scotland
G75 8RG

Study participating centre
Basildon University Hospital
Nethermayne
Basildon
England
SS16 5NL

Study participating centre
Broomfield University Hospital
Broomfield Hospital
Court Road
Chelmsford
England
CM1 7ET

Study participating centre
Raigmore Hospital
Old Perth Rd
Inverness
Scotland
IV2 3UJ

Study participating centre
Torbay Hospital
Newton Road
Torquay
England
TQ2 7AA

Study participating centre
University Hospital Southampton
Tremona Road
Southampton
England
SO16 6YD

Sponsor information

Organisation
King's College Hospital NHS Foundation Trust

ROR
<https://ror.org/01n0k5m85>

Funder(s)

Funder type

Government

Funder Name

Efficacy and Mechanism Evaluation Programme

Alternative Name(s)

NIHR Efficacy and Mechanism Evaluation Programme, Efficacy and Mechanism Evaluation (EME), EME

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the results publication

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes